<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707001</url>
  </required_header>
  <id_info>
    <org_study_id>1U/2020</org_study_id>
    <nct_id>NCT04707001</nct_id>
  </id_info>
  <brief_title>Urinary Retention After Arthroplasty</brief_title>
  <acronym>UREA</acronym>
  <official_title>Urinary Retention After Arthroplasty - UREA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Finland Hospital District</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Eastern Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Finland Hospital District</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arthroplasty increases the risk of postoperative urinary retention. Treatment of&#xD;
      postoperative urinary retention is indwelling or intermittent catheterization. The need for&#xD;
      catheterization is most commonly determined with an ultrasound scanner. Catheterization&#xD;
      increases the risk of urinary tract infection, which may further lead to haematogenic&#xD;
      infection of the artificial joint. There is no evidence of an optimal way to monitor the&#xD;
      onset of spontaneous urination.&#xD;
&#xD;
      The aim of the study is to determine whether monitoring the onset of spontaneous urination&#xD;
      after fast track knee arthroplasty is safe based on symptoms alone without ultrasound&#xD;
      monitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients undergoing knee arthroplasty will be recruited to this study. Participants&#xD;
      will be randomized to the ultrasound monitoring group or the symptoms alone group. In the&#xD;
      symptoms alone group, urination is monitored by asking at regular intervals about the onset&#xD;
      of spontaneous urination and the patient is catheterized only on a symptomatic basis or if&#xD;
      spontaneous voiding has not started 10 hours after the spinal anesthesia. Symptoms that&#xD;
      indicate catheterization are lower abdominal pain or need to void. In the ultrasound group,&#xD;
      urinary retention is monitored according to current practice with an ultrasound scanner and&#xD;
      the patient is catheterized if residual urine exceeds 800 ml or if the patient is&#xD;
      symptomatic.&#xD;
&#xD;
      The primary outcome variable is the change in IPSS score from the baseline to 3 months after&#xD;
      the procedure. The baseline score is evaluated preoperatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open label</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>IPSS questionnaire compared to IPSS before surgery. The minimum score is 0. The maximum score is 35. Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>IPSS questionnaire compared to IPSS before surgery. The minimum score is 0. The maximum score is 35. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of urinary complications</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Incidence of urinary complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (15D) score</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Health-related quality of life(15D) score compared to 15D score before surgery. The minimum score is 0. The maximum score is 1. Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of urinary complications</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Incidence of urinary complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (15D) score</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Health-related quality of life(15D) score compared to 15D score before surgery. The minimum score is 0. The maximum score is 1. Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Urinary Retention Postoperative</condition>
  <condition>Arthroplasty Complications</condition>
  <arm_group>
    <arm_group_label>Ultrasound monitoring group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the ultrasound group, urinary retention is monitored, according to current practice, with an ultrasound scanner and the patient is catheterized if necessary, if residual urine exceeds 800 ml, or if the patient is symptomatic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptoms alone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Urination is monitored by asking at regular intervals about the onset of spontaneous urination and the patient is catheterized only on a symptomatic basis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Catheterization based on ultrasound</intervention_name>
    <description>Bladder volume ultrasound</description>
    <arm_group_label>Ultrasound monitoring group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Catheterization based on evaluation of symptoms</intervention_name>
    <description>Ask for symptoms: Need to urinate, lower abdominal pain</description>
    <arm_group_label>Symptoms alone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  elective total knee arthroplasty&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous surgery for urologic cancer&#xD;
&#xD;
          -  fracture as indication for surgery&#xD;
&#xD;
          -  lack of co-operation&#xD;
&#xD;
          -  untreated urinary retention&#xD;
&#xD;
          -  nephrostoma&#xD;
&#xD;
          -  general anesthesia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>in 1:1 ratio. Participant eligibility is based on self-representation of gender identity.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juha Paloneva, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief medical director</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heikki Seikkula, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juho Sippola, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Konsta Pamilo, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonne Åkerla, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aleksi Reito, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pirkko Kinnunen</last_name>
    <role>Study Chair</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juha Paloneva, professor</last_name>
    <phone>014 269 1680</phone>
    <email>juha.paloneva@ksshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juho Sippola, MD</last_name>
    <phone>014 269 1908</phone>
    <email>juho.sippola@ksshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Finland Hospital Nova</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Juha Paloneva, MD, PhD</last_name>
      <phone>+358 14 2693119</phone>
    </contact>
    <contact_backup>
      <last_name>Juho Sippola, MD</last_name>
      <phone>+358 14 2691908</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

